2 active not recruiting, 1 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Parotid Neoplasms: new trials by email Literature Review of Parotid Neoplasms trials Research Report on Parotid Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Customized 3D Printed Oral Stents During Head and Neck Radiotherapy Best Practice, Medical Device Usage and Evaluation - Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 88 | 2021-05-26 | 2026-10-06 |
| Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery Bevonescein - Parotid Neoplasm, Thyroid Neoplasms | Phase 1 / Phase 2 | Completed | Alume Biosciences, Inc. | 27 | 2020-06-18 | 2025-05-08 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) pembrolizumab - Advanced Cancer, Anal Carcinoma | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 1609 | 2015-12-18 | 2025-09-22 |
Thyroid Neoplasms (2) · Anus Neoplasms (1) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoid Tumor (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Maxillary Sinus Neoplasms (1) · Mesothelioma (1) · Microsatellite Instability (1) · Mouth Neoplasms (1) · Neuroendocrine Tumors (1)
Mouth Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Parotid Diseases (3) · Salivary Gland Diseases (3) · Stomatognathic Diseases (3) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Head and Neck Neoplasms (2) · Mouth Neoplasms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Salivary Gland Neoplasms (2) · Thyroid Diseases (2) · Adenocarcinoma (1)
Practice Guidelines as Topic (1) · Standard of Care (1) · pembrolizumab (1)
Alume Biosciences, Inc. (1) · M.D. Anderson Cancer Center (1) · Merck Sharp & Dohme LLC (1)
United States (2)
Anna Lee (1)
PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33836153, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36748723, PMID 39979665, PMID 40121391, PMID 40595556, PMID 41920388
2015 (1)